241 related articles for article (PubMed ID: 35076300)
21. Clinical impact of
Albisinni S; Artigas C; Aoun F; Biaou I; Grosman J; Gil T; Hawaux E; Limani K; Otte FX; Peltier A; Sideris S; Sirtaine N; Flamen P; van Velthoven R
BJU Int; 2017 Aug; 120(2):197-203. PubMed ID: 27981732
[TBL] [Abstract][Full Text] [Related]
22. [
Perry E; Talwar A; Taubman K; Ng M; Wong LM; Booth R; Sutherland TR
Eur J Nucl Med Mol Imaging; 2021 Jun; 48(6):2038-2046. PubMed ID: 33399941
[TBL] [Abstract][Full Text] [Related]
23. Prospective Evaluation of
Song H; Harrison C; Duan H; Guja K; Hatami N; Franc BL; Moradi F; Aparici CM; Davidzon GA; Iagaru A
J Nucl Med; 2020 Apr; 61(4):546-551. PubMed ID: 31628216
[No Abstract] [Full Text] [Related]
24. Does Choline PET/CT Change the Management of Prostate Cancer Patients With Biochemical Failure?
Goldstein J; Even-Sapir E; Ben-Haim S; Saad A; Spieler B; Davidson T; Berger R; Weiss I; Appel S; Lawrence YR; Symon Z
Am J Clin Oncol; 2017 Jun; 40(3):256-259. PubMed ID: 25319322
[TBL] [Abstract][Full Text] [Related]
25. PSMA-targeted Radiotracers versus
Tan N; Oyoyo U; Bavadian N; Ferguson N; Mukkamala A; Calais J; Davenport MS
Radiology; 2020 Jul; 296(1):44-55. PubMed ID: 32396045
[TBL] [Abstract][Full Text] [Related]
26. Clinical Usefulness of Prostate-specific Membrane Antigen-ligand Positron Emission Tomography/Computed Tomography for the Detection of Prostate Cancer Biochemical Recurrence after Primary Radiation Therapy in Patients with Prostate-specific Antigen Below the Phoenix Threshold: Systematic Review and Meta-analysis.
Subiela JD; Gomis Sellés E; Maldonado A; Lopez Campos F; Aumatell Ovide J; Ajuria Illarramendi O; González-Padilla DA; Gajate P; Ortega Polledo LE; Alonso Y Gregorio S; Guerrero-Ramos F; Gómez Dos Santos V; Rodríguez-Patrón R; Calais J; Kishan AU; Burgos Revilla FJ; Couñago F
Clin Oncol (R Coll Radiol); 2023 Dec; 35(12):e676-e688. PubMed ID: 37802722
[TBL] [Abstract][Full Text] [Related]
27. The use of
Meredith G; Wong D; Yaxley J; Coughlin G; Thompson L; Kua B; Gianduzzo T
BJU Int; 2016 Oct; 118 Suppl 3():49-55. PubMed ID: 27659411
[TBL] [Abstract][Full Text] [Related]
28. High detection rate in [
Watabe T; Uemura M; Soeda F; Naka S; Ujike T; Hatano K; Sasaki H; Kamiya T; Shimosegawa E; Kato H; Cardinale J; Tateishi U; Nonomura N; Giesel FL
Ann Nucl Med; 2021 Apr; 35(4):523-528. PubMed ID: 33661475
[TBL] [Abstract][Full Text] [Related]
29. [Diagnostic performance of 68GA-PSMA PET/CTin patients with prostate cancer].
Veliev EI; Tomilov AA; Goncharuk DA; Bogdanov AB; Golubtsova EN
Urologiia; 2018 Jul; (3):105-110. PubMed ID: 30035428
[TBL] [Abstract][Full Text] [Related]
30. The role of 68Ga-PSMA PET/CT scan in biochemical recurrence after primary treatment for prostate cancer: a systematic review of the literature.
Eissa A; Elsherbiny A; Coelho RF; Rassweiler J; Davis JW; Porpiglia F; Patel VR; Prandini N; Micali S; Sighinolfi MC; Puliatti S; Rocco B; Bianchi G
Minerva Urol Nefrol; 2018 Oct; 70(5):462-478. PubMed ID: 29664244
[TBL] [Abstract][Full Text] [Related]
31. Efficacy, Predictive Factors, and Prediction Nomograms for
Rauscher I; Düwel C; Haller B; Rischpler C; Heck MM; Gschwend JE; Schwaiger M; Maurer T; Eiber M
Eur Urol; 2018 May; 73(5):656-661. PubMed ID: 29358059
[TBL] [Abstract][Full Text] [Related]
32. Oligometastatic disease in biochemical recurrence of prostate cancer: Prevalence on PSMA PET/CT and consecutive metastasis-directed therapy - Experience at a tertiary referral center.
Müller PJ; Dietlein M; Kobe C; Heidenreich A; Drzezga A
Nuklearmedizin; 2022 Aug; 61(4):314-324. PubMed ID: 35388442
[TBL] [Abstract][Full Text] [Related]
33. Early lesion detection with
Wondergem M; Jansen BHE; van der Zant FM; van der Sluis TM; Knol RJJ; van Kalmthout LWM; Hoekstra OS; van Moorselaar RJA; Oprea-Lager DE; Vis AN
Eur J Nucl Med Mol Imaging; 2019 Aug; 46(9):1911-1918. PubMed ID: 31230088
[TBL] [Abstract][Full Text] [Related]
34. Prospective Comparison of 18F-Fluoromethylcholine Versus 68Ga-PSMA PET/CT in Prostate Cancer Patients Who Have Rising PSA After Curative Treatment and Are Being Considered for Targeted Therapy.
Morigi JJ; Stricker PD; van Leeuwen PJ; Tang R; Ho B; Nguyen Q; Hruby G; Fogarty G; Jagavkar R; Kneebone A; Hickey A; Fanti S; Tarlinton L; Emmett L
J Nucl Med; 2015 Aug; 56(8):1185-90. PubMed ID: 26112024
[TBL] [Abstract][Full Text] [Related]
35. The clinical efficacy of PSMA PET/MRI in biochemically recurrent prostate cancer compared with standard of care imaging modalities and confirmatory histopathology: results of a single-centre, prospective clinical trial.
Joshi A; Roberts MJ; Perera M; Williams E; Rhee H; Pryor D; Lehman M; Heathcote P; Wood S; Coucher J; Gustafson S; Miles K; Vela I
Clin Exp Metastasis; 2020 Aug; 37(4):551-560. PubMed ID: 32519046
[TBL] [Abstract][Full Text] [Related]
36.
Ulaner GA; Thomsen B; Bassett J; Torrey R; Cox C; Lin K; Patel T; Techasith T; Mauguen A; Rowe SP; Lindenberg L; Mena E; Choyke P; Yoshida J
Radiology; 2022 Nov; 305(2):419-428. PubMed ID: 35852431
[TBL] [Abstract][Full Text] [Related]
37. Use and Impact of Positron Emission Tomography/Computed Tomography Prior to Salvage Radiation Therapy in Men with Biochemical Recurrence After Radical Prostatectomy: A Scoping Review.
Valle L; Shabsovich D; de Meerleer G; Maurer T; Murphy DG; Nickols NG; Vapiwala N; Calais J; Kishan AU
Eur Urol Oncol; 2021 Jun; 4(3):339-355. PubMed ID: 33637464
[TBL] [Abstract][Full Text] [Related]
38.
Davies A; Foo M; Gan CL; Kourambas J; Redgrave N; Donnellan S; Appu S; Williams S; Coleman A; Segelov E; Bradley J; Soo G; Ramdave S; Kwan EM; Azad AA
Asia Pac J Clin Oncol; 2022 Oct; 18(5):e204-e210. PubMed ID: 34161628
[TBL] [Abstract][Full Text] [Related]
39. PSMA-Based [(18)F]DCFPyL PET/CT Is Superior to Conventional Imaging for Lesion Detection in Patients with Metastatic Prostate Cancer.
Rowe SP; Macura KJ; Mena E; Blackford AL; Nadal R; Antonarakis ES; Eisenberger M; Carducci M; Fan H; Dannals RF; Chen Y; Mease RC; Szabo Z; Pomper MG; Cho SY
Mol Imaging Biol; 2016 Jun; 18(3):411-9. PubMed ID: 27080322
[TBL] [Abstract][Full Text] [Related]
40. Prostate-specific membrane antigen-positron emission tomography/computed tomography (PSMA-PET/CT)-guided stereotactic ablative body radiotherapy for oligometastatic prostate cancer: a single-institution experience and review of the published literature.
Ong WL; Koh TL; Lim Joon D; Chao M; Farrugia B; Lau E; Khoo V; Lawrentschuk N; Bolton D; Foroudi F
BJU Int; 2019 Nov; 124 Suppl 1():19-30. PubMed ID: 31507035
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
